CV 1153

Drug Profile

CV 1153

Latest Information Update: 13 May 2011

Price : $50

At a glance

  • Originator Maxim Pharmaceuticals
  • Class Antineoplastics
  • Mechanism of Action Caspase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Liver disorders; Multiple organ failure; Myocardial infarction; Septic shock; Stroke

Most Recent Events

  • 13 May 2011 Discontinued - Preclinical for Liver disorders in USA (IV)
  • 13 May 2011 Discontinued - Preclinical for Multiple organ failure in USA (IV)
  • 13 May 2011 Discontinued - Preclinical for Myocardial infarction in USA (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top